Literature DB >> 23244049

Prospects for tuberculosis elimination.

Christopher Dye1, Philippe Glaziou, Katherine Floyd, Mario Raviglione.   

Abstract

The target for TB elimination is to reduce annual incidence to less than one case per million population by 2050. Meeting that target requires a 1,000-fold reduction in incidence in little more than 35 years. This can be achieved only by combining the effective treatment of active TB-early case detection and high cure rates to interrupt transmission-with methods to prevent new infections and to neutralize existing latent infections. Vigorous implementation of the WHO Stop TB Strategy is needed to achieve the former, facilitated by the effective supply of, and demand for, health services. The latter calls for new technology, including biomarkers of TB risk, diagnostics, drugs, and vaccines. An important milestone en route to elimination will be reached when there is less than 1 TB death per 100,000 population, marking entry into the elimination phase. This landmark can be reached by many countries within 1-2 decades.

Entities:  

Mesh:

Year:  2012        PMID: 23244049     DOI: 10.1146/annurev-publhealth-031912-114431

Source DB:  PubMed          Journal:  Annu Rev Public Health        ISSN: 0163-7525            Impact factor:   21.981


  148 in total

1.  Perspective: Weigh all TB risks.

Authors:  Christopher Dye; Mario Raviglione
Journal:  Nature       Date:  2013-10-10       Impact factor: 49.962

2.  A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants.

Authors:  M Tameris; D A Hokey; V Nduba; J Sacarlal; F Laher; G Kiringa; K Gondo; E M Lazarus; G E Gray; S Nachman; H Mahomed; K Downing; B Abel; T J Scriba; J B McClain; M G Pau; J Hendriks; V Dheenadhayalan; S Ishmukhamedov; A K K Luabeya; H Geldenhuys; B Shepherd; G Blatner; V Cardenas; R Walker; W A Hanekom; J Sadoff; M Douoguih; L Barker; M Hatherill
Journal:  Vaccine       Date:  2015-04-28       Impact factor: 3.641

Review 3.  The role of B cells and humoral immunity in Mycobacterium tuberculosis infection.

Authors:  John Chan; Simren Mehta; Sushma Bharrhan; Yong Chen; Jacqueline M Achkar; Arturo Casadevall; JoAnne Flynn
Journal:  Semin Immunol       Date:  2014-10-28       Impact factor: 11.130

4.  Latent tuberculosis infection: An overview.

Authors:  S Kiazyk; T B Ball
Journal:  Can Commun Dis Rep       Date:  2017-03-02

5.  Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis.

Authors:  Xin Zhang; Matthew E Falagas; Konstantinos Z Vardakas; Rui Wang; Rong Qin; Jin Wang; Youning Liu
Journal:  J Thorac Dis       Date:  2015-04       Impact factor: 2.895

6.  Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons.

Authors:  Timothy R Sterling; Nigel A Scott; Jose M Miro; Guilherme Calvet; Alberto La Rosa; Rosa Infante; Michael P Chen; Debra A Benator; Fred Gordin; Constance A Benson; Richard E Chaisson; M Elsa Villarino
Journal:  AIDS       Date:  2016-06-19       Impact factor: 4.177

7.  Heterologous boosting with recombinant VSV-846 in BCG-primed mice confers improved protection against Mycobacterium infection.

Authors:  Ming Zhang; Chunsheng Dong; Sidong Xiong
Journal:  Hum Vaccin Immunother       Date:  2016-12-14       Impact factor: 3.452

8.  Health Care Visits as a Risk Factor for Tuberculosis in Taiwan: A Population-Based Case-Control Study.

Authors:  Sung-Ching Pan; Chien-Chou Chen; Yi-Ting Chiang; Hsing-Yi Chang; Chi-Tai Fang; Hsien-Ho Lin
Journal:  Am J Public Health       Date:  2016-05-19       Impact factor: 9.308

9.  Helminth-induced arginase-1 exacerbates lung inflammation and disease severity in tuberculosis.

Authors:  Leticia Monin; Kristin L Griffiths; Wing Y Lam; Radha Gopal; Dongwan D Kang; Mushtaq Ahmed; Anuradha Rajamanickam; Alfredo Cruz-Lagunas; Joaquín Zúñiga; Subash Babu; Jay K Kolls; Makedonka Mitreva; Bruce A Rosa; Rosalio Ramos-Payan; Thomas E Morrison; Peter J Murray; Javier Rangel-Moreno; Edward J Pearce; Shabaana A Khader
Journal:  J Clin Invest       Date:  2015-11-16       Impact factor: 14.808

10.  Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial.

Authors:  Robert Belknap; David Holland; Pei-Jean Feng; Joan-Pau Millet; Joan A Caylà; Neil A Martinson; Alicia Wright; Michael P Chen; Ruth N Moro; Nigel A Scott; Bert Arevalo; José M Miró; Margarita E Villarino; Marc Weiner; Andrey S Borisov
Journal:  Ann Intern Med       Date:  2017-11-07       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.